Numinus is a publicly traded company that was granted a license to cultivate psilocybin-containing species of mushrooms using spores and to extract psilocybin. Numinus harvested its first flush of magic mushrooms on October 22, 2020.
Numinus is dedicated to the study of psychedelic therapies, including psilocybin, MDMA, DMT, and mescaline.
Dennis McKenna, a board member of the company, said: “Mushrooms have been used in traditional medicine for literally thousands of years, and, hence, they are just that much closer to these ancient traditions. Cost should not be a barrier to access these medicines, and the use of mushroom extracts will help ensure those who need them most can benefit from psilocybin therapies.”
Mushrooms have been used in traditional medicine for literally thousands of years, and, hence, they are just that much closer to these ancient traditions. Cost should not be a barrier to access these medicines, and the use of mushroom extracts will help ensure those who need them most can benefit from psilocybin therapies.
The first runs are to test the potency, genetics, and clone the best characteristics. Numinus also applied for an amendment to the license to sell psilocybin fruiting bodies and extracts for clinical trials to other labs and research organizations.
